{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/goals-outcome-measures/nice-quality-standards/","result":{"pageContext":{"chapter":{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards","depth":2,"htmlHeader":"<!-- begin field b088ff22-7d1e-465f-a7b6-3fe8162cfe67 --><h2>NICE quality standards</h2><!-- end field b088ff22-7d1e-465f-a7b6-3fe8162cfe67 -->","summary":null,"htmlStringContent":"<!-- begin item ac9e10ec-4591-45e9-97ad-0c00fb1092c9 --><!-- begin field cf22eec9-26c9-4caa-bca3-a6fd008a7a57 --><p><strong>Quality standards that directly relate to the diagnosis and management of asthma include:</strong></p><ul><li><a data-chapter=\"quality-statement-1-developmental-objective-tests-to-support-diagnosis\" data-original-url=\"#quality-statement-1-developmental-objective-tests-to-support-diagnosis\" href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-1-developmental-objective-tests-to-support-diagnosis#quality-statement-1-developmental-objective-tests-to-support-diagnosis\" rel=\"internal\" target=\"_top\" data-hyperlink-id=\"7c5fdfd8-b834-43cc-a654-ab0a00900cd8\">Statement 1</a> People aged 5 years and over with suspected asthma have objective tests to support diagnosis. </li><li><a data-chapter=\"quality-statement-2-written-personalised-action-plan\" data-original-url=\"#quality-statement-2-written-personalised-action-plan\" href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-2-written-personalised-action-plan#quality-statement-2-written-personalised-action-plan\" rel=\"internal\" target=\"_top\" data-hyperlink-id=\"a8aa5b59-5fb2-4519-b1a4-ab0a00900d46\">Statement 2</a> People aged 5 years and over with asthma discuss and agree a written personalised action plan. </li><li><a data-chapter=\"quality-statement-3-monitoring-asthma-control\" data-original-url=\"#quality-statement-3-monitoring-asthma-control\" href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-3-monitoring-asthma-control#quality-statement-3-monitoring-asthma-control\" rel=\"internal\" target=\"_top\" data-hyperlink-id=\"d1c38d72-6681-4967-a689-ab0a00900d6a\">Statement 3</a> People with asthma have their asthma control monitored at every asthma review. </li><li><a data-chapter=\"quality-statement-4-follow-up-by-general-practice-after-emergency-care\" data-original-url=\"#quality-statement-4-follow-up-by-general-practice-after-emergency-care\" href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-4-follow-up-by-general-practice-after-emergency-care#quality-statement-4-follow-up-by-general-practice-after-emergency-care\" rel=\"internal\" target=\"_top\" data-hyperlink-id=\"0ad16b10-7219-45ff-9aad-ab0a00900d8c\">Statement 4</a> People who receive treatment in an emergency care setting for an asthma attack are followed up by their general practice within 2 working days of discharge. </li><li><a data-chapter=\"quality-statement-5-developmental-suspected-severe-asthma\" data-original-url=\"#quality-statement-5-developmental-suspected-severe-asthma\" href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-5-developmental-suspected-severe-asthma#quality-statement-5-developmental-suspected-severe-asthma\" rel=\"internal\" target=\"_top\" data-hyperlink-id=\"545a4126-3222-412d-86bf-ab0a00900dae\">Statement 5</a> People with suspected severe asthma are referred to a specialist multidisciplinary severe asthma service. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">NICE, 2018</a>] </p><p><strong>Additional quality standards that should also be considered when commissioning and providing a high-quality asthma service include:</strong></p><ul><li><a href=\"https://www.nice.org.uk/guidance/qs43/chapter/quality-statement-1-identifying-people-who-smoke\" data-hyperlink-id=\"268569e2-d4b1-46b6-b3ad-ab0a00900dcf\">Statement 1</a> People are asked if they smoke by their healthcare practitioner, and those who smoke are offered advice on how to stop.</li><li><a href=\"https://www.nice.org.uk/guidance/qs43/chapter/quality-statement-2-referral-to-smoking-cessation-services\" data-hyperlink-id=\"b6c2dcd4-f6c5-4045-b2c6-ab0a00900dea\">Statement 2</a> People who smoke are offered a referral to an evidence-based smoking cessation service.</li><li><a href=\"https://www.nice.org.uk/guidance/qs43/chapter/quality-statement-3-behavioural-support-with-pharmacotherapy\" data-hyperlink-id=\"36de635a-2000-4d0b-9c69-ab0a00900e0d\">Statement 3</a> People who smoke are offered behavioural support with pharmacotherapy by an evidence-based smoking cessation service.</li><li><a href=\"https://www.nice.org.uk/guidance/qs43/chapter/quality-statement-4-pharmacotherapy\" data-hyperlink-id=\"8658348b-5645-4e10-8a77-ab0a00900e29\">Statement 4</a> People who seek support to stop smoking and who agree to take pharmacotherapy are offered a full course.</li><li><a href=\"https://www.nice.org.uk/guidance/qs43/chapter/quality-statement-5-outcome-measurement\" data-hyperlink-id=\"6c5f5fa9-339b-4991-9bce-ab0a00900e43\">Statement 5</a> People who smoke who have set a quit date with an evidence-based smoking cessation service are assessed for carbon monoxide levels 4 weeks after the quit date.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">NICE, 2013</a>]</p><!-- end field cf22eec9-26c9-4caa-bca3-a6fd008a7a57 --><!-- end item ac9e10ec-4591-45e9-97ad-0c00fb1092c9 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}